Cyteir Therapeutics
Cambridge, US · Founded 2012 · Delaware corporation · 1 employees on LinkedIn · 13 known investors
Find your way into Cyteir Therapeutics
723 people in our graph share verified history with the Cyteir Therapeutics team — schools, employers, funds. One of them is your warm intro.
Noubar Afeyanunlockedknows Donald Corcoran · together at Massachusetts Institute of Technology (overlapped)
×3knows the team · via Massachusetts Institute of Technology
×2knows the team · via AstraZeneca Pharmaceuticals
×3knows the team · via Cornell Johnson Graduate School of Management
×3knows the team · via Stanford University School of Medicine
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.
Founders & leadership
KM
Kevin MillsinChief Scientific Officer2016–2019
RG
Ronald GoldsteininChief Financial Officer2014–2018
DC
Donald CorcoraninPresident, CEO and Director2014–2017Donald Corcoran is an executive with experience in biotech and pharmaceutical companies, including roles at startups and public entities, with background in business development, R&D operations, and fundraising across oncology and other therapeutic areas.
MR
Markus RenschlerinPresident and CEO2018–2024Markus Renschler is a board-certified medical oncologist with 25 years of experience in cancer research, including roles in drug development from basic laboratory work through approval and commercialization. He has led Cyteir Therapeutics from its founding through advancement to clinical-stage status, with prior involvement in global drug registrations across breast cancer, non-small cell lung cancer, and pancreatic cancer indications.
Board
TR
Timothy RombergerBoard director
BM
Barry MillsBoard director
Investors · 13
Droia VenturesLeuven · $540K
Lightstone VenturesPortola Valley
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Ally Bridge GroupreportedNew York
Janus Henderson InvestorsreportedLondon
Novo HoldingsreportedCopenhagen · $1.1M – $54M
Osage University PartnersreportedBala Cynwyd
RA Capitalreported · 2 sourcesBoston
VenrockreportedPalo Alto · $500K – $10M
Also in the syndicate · 4
Acuta Capital PartnersAmple Plus FundAvidity PartnersCaaS Capital Management
Reported raises · per SEC filings
Form D private placements$111.9M disclosed across 4 rounds · 2015–2021
▶$80MraisedFeb 2021 · 22 investors · BiotechnologyRule 506(b)
▶$80MraisedFeb 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- TIMOTHY ROMBERGERDirector
- PAUL SECRISTExecutive Officer
- ANDREW GENGOSExecutive Officer
- SUSAN MOLINEAUXDirector
- JOSEPH S. ZAKRZEWSKIDirector
- KAREN HONGDirector
- JANWILLEM NAESENSDirector
- JEAN GEORGEDirector
- RACQUEL BRACKENDirector
- MARKUS RENSCHLERExecutive Officer, Director
- Amount sold
- $80M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedOct 2019 · 6 investors · BiotechnologyRule 506(b)
▶$20.2MraisedOct 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JANWILLEM NAESENSDirector
- JEAN GEORGEDirector
- RACQUEL BRACKENDirector
- MARKUS RENSCHLERExecutive Officer, Director
- KAREN HONGDirector
- TIMOTHY ROMBERGERExecutive Officer, Director
- Amount sold
- $20.2M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedMay 2018 · 12 investors · BiotechnologyRule 506(b)
▶$5.8MraisedMay 2018 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bart Van HoolandDirector
- Timothy RombergerExecutive Officer, Director
- Ronald GoldsteinExecutive Officer
- Racquel BrackenDirector
- Markus RenschlerExecutive Officer, Director
- Jean GeorgeDirector
- Offering amount
- $35M
- Amount sold
- $5.8M
- Sales commissions
- $1.4M
- Placement agents
- MTS Securities, LLC
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedNov 2016 · 15 investors · Other Health CareRule 506(b)
▶$5.8MraisedNov 2016 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kevin MillsExecutive Officer, Director
- Barry MillsDirector
- Ronald GoldsteinExecutive Officer
- Donald CorcoranExecutive Officer, Director
- Timothy RombergerDirector
- Markus RenschlerDirector
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Cyteir Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Cyteir Therapeutics do?
- Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.
- Who are Cyteir Therapeutics's investors?
- Cyteir Therapeutics's investors include Droia Ventures, Lightstone Ventures, OUP (Osage University Partners), Ally Bridge Group, Janus Henderson Investors, Novo Holdings, Osage University Partners, RA Capital and 1 more.
- How much funding has Cyteir Therapeutics raised?
- Cyteir Therapeutics has disclosed $111.9M raised across 4 rounds.
- Where is Cyteir Therapeutics headquartered?
- Cyteir Therapeutics is headquartered in Cambridge, US.